IfeyinwaOsunkwoMDMPH
Hematology • Charlotte, NCSickle Cell & Other Anemias
Professor of Medicine and Pediatrics, Atrium Health and Clinical Associate Professor of Medicine, UNC Chapel Hill
Dr. Osunkwo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 980-442-5241
Summary
- Dr. Ifeyinwa Osunkwo is an oncologist in Charlotte, NC. She received her medical degree from University of Nigeria Faculty of Medicine and has been in practice 27 years. She specializes in sickle cell disease (pediatric and adult) hematologic oncology and is experienced in general / benign hematology, pediatric hematology / oncology, activities of daily living, chronic pain and anemia.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2000 - 2003
Rutgers New Jersey Medical SchoolResidency, Pediatrics, 1997 - 2000
University of Nigeria Faculty of MedicineClass of 1994
Certifications & Licensure
NC State Medical License 2014 - 2025
GA State Medical License 2004 - 2017
NJ State Medical License 2000 - 2005- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- High Dose Vitamin D for Sickle Cell Disease Start of enrollment: 2009 Feb 01
- LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study) Start of enrollment: 2019 Jan 10
Publications & Presentations
PubMed
- 109 citationsBeyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on ManagementSamir K. Ballas, Muge R. Kesen, Morton F. Goldberg, Gerard A. Lutty, Carlton Dampier
Thescientificworldjournal. 2012-08-01 - 2 citationsA comparison of the effect of patient-specific versus weight-based protocols to treat vaso-occlusive episodes in the emergency department.Paula Tanabe, Stephanie Ibemere, Ava E Pierce, Caroline E Freiermuth, Hayden B Bosworth
Academic Emergency Medicine. 2023-12-01 - 2 citationsMulticenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.Santosh L Saraf, Robert Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz
Blood Advances. 2024-08-27
Journal Articles
- A Phase 3 Trial of L-glutamine in Sickle Cell DiseaseRita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine
Press Mentions
Becker's Oncology Virtual Forum: 4 Questions with Ifeyinwa Osunkwo, Director, Sickle Cell Disease Enterprise and Professor of Medicine, Levine Cancer Institute, Atrium HealthAugust 5th, 2020
How COVID-19 Led to a Blood Shortage, and Why That’s TroublingMay 1st, 2020
‘From Nothing to Gangbusters’: A Treatment for Sickle-Cell Disease Proves Effective in AfricaDecember 1st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
